Cordyceps for Endurance

Verdict: Weak, inconsistent evidence for endurance

Cordyceps shows only a small, inconsistent endurance signal across a handful of tiny trials, so the evidence is too weak to recommend it as a genuine performance aid. Any benefit appears mostly in older or recreational exercisers and largely disappears in already-trained athletes.

C 🟠 C Weak Evidence Published

🔬Why this grade7-layer evidence engine

The grade is held to weak (Tier C) because the human evidence is thin and pulls in different directions. The single 2025 systematic review and meta-analysis (PMID 41280379) did report small gains in endurance, ventilatory threshold and VO2peak, but every one of those pooled outcomes rested on just two studies with p-values sitting right at the 0.03-0.05 edge, so the result is fragile rather than robust.

The underlying trials are small and conflicting. A 12-week trial in healthy older adults (PMID 20804368, n=20) raised the metabolic and ventilatory thresholds but left VO2max unchanged, and a 3-week study (PMID 27408987, n=28) found a VO2max gain only after chronic dosing and used a multi-mushroom blend, so the effect cannot be pinned on cordyceps alone. Critically, the trial in trained male cyclists (PMID 15118196, n=22) found no benefit at all, meaning the positive signals do not extend to fit, performance-oriented users.

Regulators and clinicians reinforce the caution. EFSA assessed a cordyceps energy/invigoration claim and judged it not supported by pertinent human data, and the UK NHS, WHO and NIH ODS offer no endorsement. The Cleveland Clinic notes the VO2max study but stresses that other studies show no effect and that more research is needed. Most products are cultured mycelium (Cs-4/CordyMax) rather than wild cordyceps, further limiting how far these modest findings can be stretched.

⚖️

Scoring transparency

All scores computed by a 7-layer evidence engine — fully auditable
Raw score 0.57
D
C
B
A
S
← counter-evidence / ineffectiveeffective / strong evidence →
Final grade
C · Published
Confidence
85%
Highly consistent evidence
Evidence level
E3
Single high-quality meta-analysis

How strongly each layer supports this effect

lower = less supportive
L1 ExamineGlobal benchmark
0.50
L11 AI re-checkIndependent read
0.50
L5 Clinical bodiesAuthoritative stance
0.52
L2 PubMedPrimary literature
0.60
L3 MechanismPlausibility
0.65
Against Mixed Supports
View the full decision path (audit trail)
  1. compute_raw_score — 加權公式: L2×0.30 + L3×0.25 + L5×0.25 + L11×0.10 + L1×0.10 = 0.572
  2. tier_from_score — 依分數區間映射至 tier letter
  3. apply_hec_rules — 高品質 SR/MA 顯示 positive (1 篇 > 0 negative)
  4. tier_strict_requirement_check — | B→C 因 scope.conflation_risk=true 且 L11 獨評較低 (B7-2 tier cap)
  5. detect_disputes — 偵測到 0 個 hard + 0 個 soft dispute
  6. decide_status — 依 tier + dispute 結果決定 status

📄PubMed studies (4)L2 · primary research & systematic reviews

Effects of fungal supplementation on endurance, immune function, and hematological profiles in adult athletes: a systematic review and meta-analysis
PMID: 41280379 2025 系統性回顧 n = 528
Finding: Pooled C. sinensis improved endurance (p=0.05, I2=20%), ventilatory threshold (p=0.03, I2=0%) and VO2peak (p=0.04, I2=0%); only 2 studies per pooled outcome.
Government
View on PubMed
Effect of Cs-4 (Cordyceps sinensis) on Exercise Performance in Healthy Older Subjects: A Double-Blind, Placebo-Controlled Trial
PMID: 20804368 2010 RCT (double-blind) n = 20
Finding: Metabolic threshold +10.5% (p<0.02) and ventilatory threshold +8.5% (p=0.031) vs no change in placebo; VO2max unchanged in both groups.
🟠 Limited quality Government Effect size: MD +10.5% metabolic threshold; +8.5% ventilatory threshold
View on PubMed
Cordyceps militaris Improves Tolerance to High-Intensity Exercise After Acute and Chronic Supplementation
PMID: 27408987 2017 RCT (double-blind) n = 28
Finding: No effect at 1 week (TTE p=0.540); after 3 weeks VO2max improved +4.8 ml/kg/min (p=0.042) vs placebo +0.9, TTE +69.8 s.
🟠 Limited quality Government Effect size: MD VO2max +4.8 ml/kg/min; TTE +69.8 s
View on PubMed
Cordyceps Sinensis (CordyMax Cs-4) supplementation does not improve endurance exercise performance
PMID: 15118196 2004 RCT (double-blind) n = 22
Finding: No significant change in VO2peak, ventilatory threshold or time trial completion within or between groups in endurance-trained male cyclists.
View on PubMed

🏛️Regulatory & authoritative positionsL4/L5 · FDA / EMA / NIH ODS / Cochrane / Mayo …

L4a US FDA
Cautious
L4b EU EFSA
Against
Scientific Opinion Part II on the substantiation of health claims related to various food(s)/food constituent(s) not supported by pertinent human data (ID 406, 462, 472, 543, 659, 678, 696, 858, 1381, 1403, 1437, 1438, 1513, 1536, 1537, 1538, 1539, 1540, 1543, 1613, 1627, 1855, 1860, 1981, 2126, 2514, 3127, 4038, 4501, 4672, 4712, 4718) pursuant to Article 13(1) of Regulation (EC) No 1924/2006 source↗
L4d TW TFDA / 衛福部
Supportive
「冬蟲夏草菌絲體食品標示相關規定」(食藥署101年2月9日署授食字第1001303885號公告,103年2月9日生效):含冬蟲夏草菌絲體之產品,應於明顯易見處加註『本產品非中藥材冬蟲夏草之製品』之醒語;應明確標示菌株之中文名稱及拉丁學名;品名應完整標示為『冬蟲夏草菌絲體』七個字,不得僅標示『冬蟲夏草』,且七個字字體大小一致;使用之菌株須為中華被毛孢(Hirsutella sinensis),或分離自冬蟲夏草之蟲草相關菌株。違規涉違反食安法第22條,依第47條處3萬至300萬元罰鍰。衛福部另說明:『目前核准3款含蟲草相關成分的健康食品』,『所核准的保健功效分別為抗疲勞、護肝及調節免疫』,3件產品皆經科學化安全及保健功效評估試驗。 source↗
L5c Cleveland Clinic
Cautious
One study followed 28 individuals who participated in high-intensity exercise over the course of three weeks while consuming a mushroom blend that contained cordyceps. That study showed significant improvement in VO2 max. ... But some studies suggest cordyceps has no effect on aerobic capacity or endurance exercise. The varying results imply there's more research needed to determine the mechani… source↗
PMID 100% verifiedevery citation checked via NCBI Entrez
🔬4 PubMed studiesindependently re-checked by multiple sub-agents
engine_version: v1.0 claim_id: CLM-COND-endurance-INT-cordyceps-001 繁體中文版 →